WARREN, N.J. - Aquestive Therapeutics , Inc. (NASDAQ: NASDAQ:AQST), a pharmaceutical company specializing in innovative drug delivery technologies, announced today the appointment of Abigail "Abbey" Jenkins to its Board of Directors. Jenkins, with over two decades of experience in the biopharmaceutical sector, brings extensive knowledge in commercial leadership and corporate strategy.
Jenkins currently serves as President and CEO of Gamida Cell Ltd. (NASDAQ: NASDAQ:GMDA) and has previously held key positions at Lyndra Therapeutics, Inc., Emergent BioSolutions, Inc. (NYSE: EBS), Aquinox Pharmaceuticals, Inc., and other notable firms. Her background includes the commercialization of pharmaceutical products and management of vaccine development from research to market.
Dan Barber, President and CEO of Aquestive, expressed confidence in Jenkins's ability to contribute significantly to the company, particularly as Aquestive advances its proprietary product Anaphylm™, an orally administered epinephrine candidate for treating anaphylaxis.
The addition of Jenkins expands Aquestive's Board to eight directors, seven of whom are independent. Santo J. Costa, Chairman of the Board, highlighted Jenkins's expertise in drug delivery systems and novel therapeutics launches as invaluable to the company's progress.
Jenkins expressed her enthusiasm for joining Aquestive during a pivotal period, citing the potential of the company's delivery technologies and the Anaphylm product.
Aquestive's portfolio includes five commercialized products and collaborations with pharmaceutical companies to bring new molecules to market. The firm focuses on central nervous system diseases and severe allergic reactions, including anaphylaxis.
This announcement is based on a press release statement and contains forward-looking statements regarding the clinical development and potential FDA approval of Anaphylm™. These statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
InvestingPro Insights
As Aquestive Therapeutics welcomes Abigail Jenkins to its Board of Directors, investors and industry observers are closely monitoring the company's performance metrics and market position. Aquestive's innovative drug delivery technologies, including the much-anticipated Anaphylm™, are key factors in the company's strategy.
With a market capitalization of $383.26 million, Aquestive is navigating through a challenging phase, as reflected in its negative P/E ratio of -34.18 for the last twelve months as of Q4 2023, and an adjusted P/E ratio of -57.36. This indicates that the market is factoring in the company's current lack of profitability, aligning with the InvestingPro Tips that analysts do not anticipate the company will be profitable this year. Additionally, the company's revenue growth has been positive, with a 6.09% increase over the last twelve months as of Q4 2023 and a quarterly surge of 23.63% in Q1 2023.
Despite these challenges, Aquestive's stock has shown remarkable resilience, with a strong return over the last three months and a large price uptick over the last six months. Specifically, the 3-month price total return as of Y2024.D92 is a striking 110.89%, and the 6-month price total return is an even more impressive 178.43%. This volatility and growth potential may appeal to certain types of investors, as highlighted by an InvestingPro Tip noting the stock's volatility.
For those considering an investment in Aquestive or seeking to understand the company's trajectory better, additional InvestingPro Tips are available, providing deeper insights into the company's financial health and market performance. There are 7 more tips listed on InvestingPro that could further inform your investment decisions. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to these valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.